SUPPLEMENTARY APPENDIX

List of Investigators
Ethical Conduct of the Study
Study Responsibilities
Testing for SARS-CoV-2 Virus and Antibodies
Determination of SARS-CoV-2 Lineage
Definitions of Confirmed and Severe COVID-19 Cases7
Table S1 Explanation of the Changes in Denominator Numbers in Various Analyses9
Table S2 Baseline Comorbidities in Participants ≥16 Years of Age10
Table S3 Participants Reporting at Least 1 Adverse Event from Dose 1 to 1 Month After Dose
2 During the Blinded Follow-up Period11
Table S4 Causes of Death from Dose 1 to Unblinding (Safety Population, ≥16 Years Old)12
Table S5 Vaccine Efficacy Overall and by Subgroup after Dose 1 During the Blinded Placebo
Controlled Follow-up Period (All-Available Population)14
Table S6 Vaccine Efficacy against Severe COVID-19 Occurrence after Dose 1 (All-Available
Population)15
Table S7 Vaccine Efficacy from 7 Days after Dose 2 by Underlying Comorbidities (Risk Status)
among Participants Without Evidence of Infection Prior to 7 Days after Dose 2 (Evaluable
Efficacy Population)

List of Investigators

Name	Institute	Location
Aberg, Judith	Icahn School of Medicine at Mount Sinai	New York, NY, USA
Addo, Marylyn	Universitätsklinikum Hamburg-Eppendorf	Hamburg, Germany
Akhan, Sıla	Kocaeli University Med	Kocaeli, Turkey
Albertson, Timothy	University of California, Davis	Sacramento, CA, USA
Al-Ibrahim, Mohamed	SNBL Clinical Pharmacology Center	Baltimore, MD, USA
Altın, Sedat	Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital	Istanbul, Turkey
Anderson, Corey	Clinical Research Consortium	Tempe, AZ, USA
Andrews, Charles	Diagnostics Research Group	San Antonio, TX, USA
Arora, Samir	Aventiv Research	Columbus, OH, USA
Balik, Ismail	Ankara University Medical School	Ankara, Turkey
Barnett, Elizabeth	Boston Medical Center	Boston, MA, USA
Bauer, George	Benchmark Research	Metairie, LA, USA
Baumann-Noss, Sybille	CRS Clinical Research Services Berlin	Berlin, Germany
Berhe, Mezgebe	North Texas Infectious Diseases Consultants	Dallas, TX, USA
Bradley, Paul	Meridian Clinical Research	Savannah, GA, USA
Brandon, Donald	California Research Foundation	San Diego, CA, USA
Brune, Daniel	Optimal Research	Peoria, IL, USA
Burgher, Abram	The Pain Center of Arizona	Peoria, AZ, USA
Butcher, Bain	Sterling Research Group	Cincinnati, OH, USA
Butuk, David	Solaris Clinical Research	Meridian, ID, USA
Cannon, Kevin	PMG Research of Wilmington	Wilmington, NC, USA
Cardona, Jose	Indago Research and Health Center	Hialeah, FL, USA
Cavelli, Rachael	State University of New York Upstate Medical University	Syracuse, NY, USA
Chalhoub, Fadi	CNS Healthcare	Jacksonville, FL, USA
Christensen, Shane	J. Lewis Research	Salt Lake City, UT, USA
Christensen, Tom	Waterway Family Medicine	Little River, SC, USA
Chu, Laurence	Benchmark Research	Austin, TX, USA
Cox, Steven	Lynn Institute of Norman	Norman, OK, USA
Crook, Gretchen	Austin Regional Clinic: ARC Wilson Parke	Austin, TX, USA
Davis, Matthew	Rochester Clinical Research	Rochester, NY, USA
Davit, Rajesh	Sterling Research Group	Cincinnati, OH, USA
Denham, Douglas	Clinical Trials of Texas (CTT)	San Antonio, TX, USA
Dever, Michael	Clinical Neuroscience Solutions	Orlando, FL, USA
Donskey, Curtis	Louis Stokes Cleveland VA Medical Center	Cleveland, OH, USA
Doust, Matthew	Hope Research Institute	Phoenix, AZ, USA
Dunn, Michael	Quality Clinical Research	Omaha, NE, USA
Earl, John	PMG Research of Hickory	Hickory, NC, USA
Eder, Frank	United Medical Associates - Meridian Clinical Research	Binghamton, NY, USA
Eich, Andreas	IKF Pneumologie	Frankfurt, Germany
Ensz, David	Meridian Clinical Research	Dakota Dunes, SD, USA
Essink, Brandon	Meridian Clinical Research	Omaha, NE, USA
Falcone, Robert	Amici Clinical Research	Raritan, NJ, USA
Falsey, Ann	University of Rochester/Rochester General Hospital	Rochester, NY, USA
		, ,

Finberg, Robert Finn, Daniel Fitz-Patrick, David Fortmann, Stephen Fouche, Leon Fragoso, Veronica Frenck, Robert Fried, David Fuller, Gregory Fussell, Suzanne Garcia-Diaz, Julia Gentry, Andrew Glover, Richard Greenbaum, Carla Grubb, Stephen Hammitt, Laura

Harper, Charles Harper, Wayne Hartman, Aaron Heller, Robert Hendrix, Ernest Herrington, Darrell Jennings, Timothy Karabay, Oğuz Kaster, Steven Katzman, Steven Kingsley, Jeffrey Klein, Nicola

Klein, Tracy Koch, Mark Köksal, Iftahar Koren, Michael Kutner, Mark Lee, Marcus Leibowitz, Mark Levin, Michael Libster, Romina Lillestol, Michael Lucasti, Christopher Luttermann, Matthias Manning, Mary Beth Martin, Earl

Matherne, Paul

University of Massachusetts Medical School Kentucky Pediatric/Adult Research East-West Medical Research Institute Kaiser Permanente Center for Health Research Tambotie Medical Centre Texas Center for Drug Development Cincinnati Children's Hospital Omega Medical Research Ventavia Research Group Long Beach Clinical Trials Services Ochsner Health Bozeman Health Clinical Research Alliance for Multispecialty Research Benaroya Research Institute at Virginia Mason Main Street Physicians Johns Hopkins Center for American Indian Health Meridian Clinical Research Wake Research Virginia Research Center Bayview Research Group North Alabama Research Center Benchmark Research Clinical Research Professionals Sakarya University Faculty of Medicine Confluence Health/Wenatchee Valley Hospital & Clinics Michigan Center for Medical Research Columbus Regional Research Institute Kaiser Permanente, Northern California

Heartland Research Associates Ventavia Research Group Acibadem University Hospital Atakent Jacksonville Center for Clinical Research Suncoast Research Group Trinity Clinical Research National Research Institute Clinical Research Center of Nevada Fundacion INFANT Lillestol Research South Jersey Infectious Disease Studienzentrum Brinkum Dr. Lars Pohlmeier und Torsten Drescher Velocity Clinical Research Martin Diagnostic Clinic MedPharmics

Worcester, MA, USA Bardstown, KY, USA Honolulu, HI, USA Portland, OR, USA Thabazimbi, South Africa Houston, TX, USA Cincinnati, OH, USA Warwick, RI, USA Keller, TX, USA Long Beach, CA, USA New Orleans, LA, USA Bozeman, MT, USA Newton, KS, USA Seattle, WA, USA Little River, SC, USA Whiteriver, AZ, USA Chinle, AZ, USA Shiprock, NM, USA Gallup, NM, USA Norfolk, NE, USA Raleigh, NC, USA Midlothian, VA, USA Valley Village, CA, USA Athens, AL, USA San Angelo, TX, USA Chesterfield, MO, USA Sakarya, Turkey Wenatchee, WA, USA Farmington Hills, MI, USA Columbus, GA, USA Santa Clara, CA, USA Sacramento, CA, USA Wichita, KS, USA Fort Worth, TX, USA Istanbul, Turkey Jacksonville, FL, USA Miami, FL, USA Tullahoma, TN, USA Huntingdon Park, CA, USA Las Vegas, NV, USA Buenos Aires, Argentina Fargo, ND, USA Somers Point, NJ, USA Stuhr, Germany Cleveland, OH, USA Tomball, TX, USA Gulfport, MS, USA

McMurray, James Mert, Ali Middleton, Randle Mitha, Essack Morawski, Emily Moreira, Edson Murray, Alexander Mussaji, Murtaza Musungaie, Dany Nell, Haylene Odekirk, Larry Ogbuagu, Onyema Paolino, Kristopher Patel, Suchet Peterson, James Pickrell, Paul Polack, Fernando Poretz, Donald Raad, George Randall, William Rankin, Bruce Reynolds, Steven Riesenberg, Robert Rodriguez, Hector Rosen, Jeffrey Rubino, John Rupp, Richard Saiger, Salma Salata, Robert Saleh, Jamshid Schaefer, Axel Schear, Martin Schultz, Armin Schwartz, Howard Segall, Nathan Seger, William Senders, Shelly Sharp, Stephan Shoffner, Sylvia Simsek Yavuz, Serap Sligh, Teresa Smith, William Stacey, Helen Stephens, Michael Studdard, Harry Tabak, Fehmi Talaat, Kawsar

Medical Affiliated Research Center (MARC) Medipol University Hospital **Optimal Research** Newtown Clinical Research Holston Medical Group Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation PharmQuest LinQ Research Jongaie Research Tiervlei Trial Centre, Karl Bremer Hospital Lynn Institute of Denver Yale University School of Medicine State University of New York, Upstate Medical University Regional Clinical Research J. Lewis Research Tekton Research Fundacion INFANT Clinical Alliance for Research and Education PMG Research of Charlotte PriMed Clinical Research Accel Research Sites - DeLand Clinical Research Unit Collaborative Neuroscience Network Atlanta Center for Medical Research Acevedo Clinical Research Associates Clinical Research of South Florida Raleigh Medical Group, PA University of Texas Research Across America University Hospitals Cleveland Medical Center Northern California Neurological Surgery Medizentrum Essen Borbeck Dayton Clinical Research CRS Clinical Research Services Mannheim Research Centers of America Clinical Research Atlanta HealthFirst Medical Group Senders Pediatrics Clinical Research Associates PMG Research of Cary Istanbul Faculty of Medicine, Istanbul University Providence Clinical Research New Orleans Center for Clinical Research Diablo Clinical Research Fleming Island Center for Clinical Research Coastal Clinical Research Istanbul University Cerrahpaşa Medical School Johns Hopkins School of Medicine

Huntsville, AL, USA Istanbul, Turkey Huntsville, AL, USA Johannesburg, South Africa Kingsport, TN, USA Bahia, Brazil Greensboro, NC, USA Houston, TX, USA Pretoria, South Africa Cape Town, South Africa Denver, CO, USA New Haven, CT, USA Syracuse, NY, USA Endwell, NY, USA Salt Lake City, UT, USA Austin, TX, USA Buenos Aires, Argentina Annandale, VA, USA Charlotte, NC, USA Dayton, OH, USA DeLand, FL, USA Long Beach, CA, USA Atlanta, GA, USA Miami, FL, USA Coral Gables, FL, USA Raleigh, NC, USA Galveston, TX, USA Mesquite, TX, USA Cleveland, OH, USA Redding, CA, USA Essen, Germany Dayton, OH, USA Mannheim, Germany Hollywood, FL, USA Stockbridge, GA, USA Fort Worth, TX, USA South Euclid, OH, USA Nashville, TN, USA Cary, NC, USA Istanbul, Turkey North Hollywood, CA, USA New Orleans, LA, USA Walnut Creek, CA, USA Fleming Island, FL, USA Mobile, AL, USA Istanbul, Turkey Baltimore, MD, USA

Thomas, Stephen	State University of New York, Upstate Medical University	Syracuse, NY, USA
Towner, William	Kaiser Permanente	Los Angeles, CA, USA
Tran, Van	Ventavia Research Group	Houston, TX, USA
Ünal, Serhat	Hacettepe University	Ankara, Turkey
Usdan, Lisa	CNS Healthcare	Memphis, TN, USA
Vanchiere, John	Louisiana State University Health Shreveport	Shreveport, LA, USA
Varano, Susann	Clinical Research Consulting	Milford, CT, USA
Wadsworth, L. Tyler	Sundance Clinical Research	St Louis, MO, USA
Walsh, Edward	University of Rochester/Rochester General Hospital	Rochester, NY, USA
Walter, Emmanuel	Duke Human Vaccine Institute	Durham, NC, USA
Wappner, Diego	Fundacion INFANT	Buenos Aires, Argentina
Whiles, Rick	Holston Medical Group	Bristol, TN, USA
Williams, Hayes	Achieve Clinical Research	Birmingham, AL, USA
Wilson, Jonathan	Piedmont Medical Research of Winston-Salem	Winston-Salem, NC, USA
Winkle, Peter	Anaheim Clinical Trials	Anaheim, CA, USA
Winokur, Patricia	University of Iowa	Iowa City, IA, USA
Wolf, Thomas	Prairie Fields Family Medicine	Fremont, NE, USA
Yozviak, Joseph	Lehigh Valley Hospital Cedar Crest	Allentown, PA, USA
Zerbini, Cristiano	Centro Paulista de Investigação Clínica - CEPIC	São Paulo, Brazil

Ethical Conduct of the Study

The trial was conducted in accordance with the protocol, the ethical principles derived from international guidelines including the International Council for Harmonisation Good Clinical Practice Guidelines, the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, and applicable laws and regulations (including applicable privacy laws). An independent data monitoring committee reviewed efficacy and unblinded safety data. Institutional Review Board or Ethics Committee approval was obtained for each site prior to enrollment of any study participant.

The list of Institutional Review Board Committees is summarized at the end of this Supplementary Appendix.

Study Responsibilities

Pfizer was responsible for the design, study conduct, data collection, data analysis, data interpretation, and writing of this manuscript. Both Pfizer and BioNTech manufactured clinical trial material. BioNTech was the sponsor of the study and contributed to data interpretation and writing of the manuscript. All study data were available to all authors who vouch for its accuracy and adherence of the study to the protocol.

Testing for SARS-CoV-2 Virus and Antibodies

Testing for SARS-CoV-2 virus was conducted using the Cepheid Xpert Xpress SARS-CoV-2 RT-PCR test. Testing for SARS-CoV-2 antibodies was conducted using the Roche Elecsys[®] Anti-SARS-CoV-2 antibody test.

Determination of SARS-CoV-2 Lineage

For determination of SARS-CoV-2 lineage, nucleic acid extraction of midturbinate swab specimens was performed using the MagMAXTM Viral/Pathogen Ultra Nucleic Acid Isolation Kit processed on a KingFisherTM Presto.

SARS-CoV-2 viral genome sequencing was performed using the Ion Torrent and Illumina NextSeq platforms. For the Ion Torrent sequencing platform, the Ion AmpliSeq[™] SARS-CoV-2 Research Panel was used, which consists of 2 primer pools targeting a total of 237 PCR amplicons specific to SARS-CoV-2 and 5 human expression controls in each pool. Oligonucleotide primers based on available SARS-CoV-2 nucleotide sequences direct the amplification of the viral genome with amplicon lengths of 125–275 bp. The panel provides >99% coverage of the SARS-CoV-2 genome (~30 kb). To determine the optimal number of target amplification cycles, SARS-CoV-2 viral RNA content in the nucleic acid purified from the midturbinate specimens was quantified using the TaqMan[™] 2019-nCoV Assay Kit v1, the TaqMan[™] 2019-nCoV Control Kit v1, and TaqPath[™] 1-Step RT-qPCR Master Mix, CG. cDNA was synthesized with the SuperScript VILO cDNA synthesis kit. Libraries were prepared using the Ion AmpliSeq[™] Library Kit plus the Ion AmpliSeq[™] SARS-CoV-2 Research Panel according to the

manufacturer's instructions (ThermoFisher. Ion AmpliSeq[™] Library Kit Plus USER GUIDE. Publication MAN0017003 version C.0.). Libraries underwent template preparation with Ion Chef according to the manufacturer's instructions. Prepared templates were loaded onto an Ion 530 chip for semiconductor sequencing on the Ion GeneStudio[™] S5 plus sequencer according to the manufacturer's instructions. Raw sequencing reads generated by the Ion Torrent sequencer were quality and adaptor trimmed by Ion Torrent Suite and the resulting reads were then mapped to the complete genome of the SARS-CoV-2 Wuhan-Hu-1 isolate (GenBank accession number MN908947.3) using TMAP 5.14.0. Variant calling was carried out with the Torrent Variant Caller using the BAM file from the mapping of the cleaned sequence reads onto the reference sequence of SARS-CoV-2.

SARS-CoV-2 viral genome sequencing performed using the Illumina NextSeq platform used the AmpliSeq for Illumina SARS-CoV-2 panel of PCR primers to enrich for SARS-CoV-2 in the biological specimen. This was a 2-pool design, containing a total of 237 SARS-CoV-2 amplicon/primer pairs plus 5 human expression controls in each pool. Oligonucleotide primers based on available SARS-CoV-2 nucleotide sequences directed the amplification of overlapping amplicons with lengths of 125–275 bp that cover >99% of the viral genome. Nucleic acid extracted from the midturbinate specimens was digested initially with DNase (Invitrogen TURBO DNA-freeTM Kit, AM1907), and RNA was purified using MagMAXTM beads before cDNA synthesis. Synthesis of cDNA using random sequence primers and downstream steps were as described by the manufacturer. SARS-CoV-2 amplicons were generated from the cDNA, followed by ligation of Universal Next Generation Sequencing Adaptors to the ends of the amplicons. Amplicon libraries were purified with magnetic beads and loaded onto a flow cell for sequence determination using the Illumina NextSeq instrument, according to the manufacturer's instructions. Sequences with \geq 30-fold coverage across the entire spike gene were advanced for viral lineage assignment. Single nucleotide variants were called using the "Low Frequency Variant Detection" function with the cut-off for sequence heterogeneity set at >10%.

SARS-CoV-2 lineage assignment was based on Pangolin 2.0 software, which runs a multinomial logistic regression model trained against lineage assignments based on isolate data from the Global Initiative on Sharing All Influenza Data (GISAID), a global science initiative established in 2008 that provides open-access to genomics data of influenza virus and SARS-CoV-2.

Definitions of Confirmed and Severe COVID-19 Cases

The definition of SARS-CoV-2-related cases was the presence of ≥ 1 of the following symptoms and SARS-CoV-2-NAAT positivity during or within 4 days before or after the symptomatic period: fever, new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea, and/or vomiting. The onset date of the case was the date that symptoms were first experienced by the participant. If new symptoms were reported ≤ 4 days after resolution of all previous symptoms, they were considered part of a single illness.

Confirmed severe COVID-19 required confirmation of COVID-19 and the presence of ≥ 1 of the following: clinical signs at rest indicative of severe systemic illness (respiratory rate ≥ 30 breaths per minute, heart rate ≥ 125 beats per minute, SpO₂ $\leq 93\%$ on room air at sea level, or PaO₂/FiO₂ < 300 mmHg); respiratory failure (defined as needing high-flow oxygen, non-invasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); evidence of shock (systolic blood pressure <90 mmHg, diastolic blood pressure <60 mmHg, or requiring vasopressors); significant acute renal, hepatic,

or neurologic dysfunction; intensive care unit admission; and/or death (https://www.fda.gov/media/137926/download).

Figure/Table Number	Figure/Table Title	Population(s)/Sample Size	Explanation
Figure 1	Disposition of Participants	All enrolled safety population ≥16 years of age N=44,165	Per protocol
Figure 2	Local Reactions and Systemic Events Reported within 7 Days after Receipt of BNT162b2 or Placebo by Baseline SARS-CoV-2 Status	Reactogenicity subset of participants ≥16 years of age (ie, participants who used an electronic diary for reporting local reactions and systemic events) N=9839	Per protocol
Figure 3	Efficacy of BNT162b2 against COVID-19 Occurrence after Dose 1 During the Placebo-controlled Follow-up Period	N=46,077 (all available)	All randomized participants ≥12 years of age
Table 1	Demographics	Participants ≥16 years of age N=44,047	Includes HIV-infected individuals
Table 2	Vaccine Efficacy against COVID-19 from 7 Days after Dose 2 During the Blinded Placebo Controlled Follow- up Period (Evaluable Efficacy Population, ≥12 Years Old)	a. Efficacy endpoint including individuals without evidence of prior infection (N=42,094)	Evaluable population:received 2 vaccinations as randomizedno major protocol
ropulation, 212 Tears Old)		b. Efficacy endpoint including individuals with and those without evidence of prior infection (N=44,486)	deviations Excludes HIV+ participants
Table 3	Vaccine Efficacy Overall and by Subgroup in Participants Without Evidence of Infection Prior to 7 Days After Dose 2 During the Blinded Placebo Controlled Follow- up Period	N=42,094 (same as efficacy endpoint in Table 2, participants ≥12 years of age)	
Table S2	Baseline Comorbidities in Participants ≥16 Years of Age	N=44,047	Includes HIV-infected individuals
Table S3	Participants Reporting at Least 1 Adverse Event From Dose 1 to 1 Month After Dose 2 During the Blinded Follow-up Period	Participants ≥16 years of age N=43,847	Vaccinated minus 200 HIV- infected participants
Table S4	Causes of Death from Dose 1 to Unblinding (Safety Population, ≥16 Years Old)	Participants ≥16 years of age N=43,847	Vaccinated minus 200 HIV- infected participants
Table S5	Vaccine Efficacy Overall and by Subgroup after Dose 1 During the Blinded Placebo Controlled Follow- up Period (All-Available Population)	N=46,077 (all available)	
Table S6	Vaccine Efficacy against Severe COVID-19 Occurrence after Dose 1 (All-Available Population)	N=46,077 (all available, participants ≥12 years of age)	
Table S7	Vaccine Efficacy from 7 Days after Dose 2 by Underlying Comorbidities (Risk Status) among Participants without Evidence of Infection Prior to 7 Days after Dose 2 (Evaluable Efficacy Population)	N=42,094 (same as efficacy endpoint in Table 2, participants ≥12 years of age)	

 Table S1 | Explanation of the Changes in Denominator Numbers in Various Analyses.

Charlson Comorbidity Index Category	BNT162b2 (N ^a =22,026)	Placebo (N ^a =22,021)	Total (N ^a =44,047)
	n ^b (%)	n ^b (%)	n ^b (%)
Participants with any Charlson comorbidity	4628 (21.0)	4511 (20.5)	9139 (20.7)
AIDS/HIV	100 (0.5)	100 (0.5)	200 (0.5)
Any malignancy	812 (3.7)	757 (3.4)	1569 (3.6)
Cerebrovascular disease	227 (1.0)	198 (0.9)	425 (1.0)
Chronic pulmonary disease	1783 (8.1)	1775 (8.1)	3558 (8.1)
Congestive heart failure	109 (0.5)	102 (0.5)	211 (0.5)
Dementia	7 (0.0)	11 (0.0)	18 (0.0)
Diabetes with chronic complication	116 (0.5)	130 (0.6)	246 (0.6)
Diabetes without chronic complication	1700 (7.7)	1699 (7.7)	3399 (7.7)
Hemiplegia or paraplegia	15 (0.1)	25 (0.1)	40 (0.1)
Leukemia	14 (0.1)	11 (0.0)	25 (0.1)
Lymphoma	26 (0.1)	36 (0.2)	62 (0.1)
Metastatic solid tumor	4 (0.0)	3 (0.0)	7 (0.0)
Mild liver disease	152 (0.7)	115 (0.5)	267 (0.6)
Moderate or severe liver disease	2 (0.0)	3 (0.0)	5 (0.0)
Myocardial infarction	225 (1.0)	218 (1.0)	443 (1.0)
Peptic ulcer disease	63 (0.3)	84 (0.4)	147 (0.3)
Peripheral vascular disease	144 (0.7)	139 (0.6)	283 (0.6)
Renal disease	140 (0.6)	153 (0.7)	293 (0.7)
Rheumatic disease	75 (0.3)	71 (0.3)	146 (0.3)

Table S2 | Baseline Comorbidities in Participants \geq 16 Years of Age. Baseline comorbid conditions are classified according to the Charlson Comorbidity Index (Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51.). a. N=number of participants in the specified group. This value is the denominator for the percentage calculations. b. n=number of participants with the specified characteristic. Participants with multiple occurrences within each category are counted only once. For 'Participants with any Charlson comorbidity', n=number of participants reporting \geq 1 occurrence of any Charlson comorbidity.

Adverse Event	BNT162b2 (N ^a =21,926) n ^b (%)	Placebo (N ^a =21,921) n ^b (%)
Any event	6617 (30.2)	3048 (13.9)
Related ^c	5241 (23.9)	1311 (6.0)
Severe	262 (1.2)	150 (0.7)
Life-threatening	21 (0.1)	26 (0.1)
Any serious adverse event	127 (0.6)	116 (0.5)
Related ^{c,d}	3 (0.0)	0
Severe	71 (0.3)	66 (0.3)
Life-threatening	21 (0.1)	26 (0.1)
Any adverse event leading to withdrawal	32 (0.1)	36 (0.2)
Related ^c	13 (0.1)	11 (0.1)
Severe	10 (0.0)	10 (0.0)
Life-threatening	3 (0.0)	7 (0.0)
Death	3 (0.0)	5 (0.0)

Table S3 | Participants Reporting at Least 1 Adverse Event from Dose 1 to 1 Month After Dose 2 During the Blinded Follow-up Period. The population included all \geq 16-year-old participants who received \geq 1 dose of vaccine irrespective of follow-up time. a. N=number of participants in the specified group. This value is the denominator for the percentage calculations. b. n=Number of participants reporting \geq 1 occurrence of the specified event category. For 'any event', n=number of participants reporting \geq 1 occurrence of any event. c. Assessed by the investigator as related to investigational product. d. Shoulder injury related to vaccine administration, right axillary lymphadenopathy, and paroxysmal ventricular arrhythmia (as previously reported). Adverse events for 12–15-year-old participants were reported previously.¹¹

	BNT162b2 (N=21,926)	Placebo (N=21,921)	
Reported Cause of Death ^a	n	<u> </u>	
Deaths	15	14	
Acute respiratory failure	0	1	
Aortic rupture	0	1	
Arteriosclerosis	2	0	
Biliary cancer metastatic	0	1	
COVID-19	0	2	
COVID-19 pneumonia	1	0	
Cardiac arrest	4	1	
Cardiac failure congestive	1	0	
Cardiorespiratory arrest	1	1	
Chronic obstructive pulmonary disease	1	0	
Death	0	1	
Dementia	0	1	
Emphysematous cholecystitis	1	0	
Hemorrhagic stroke	0	1	
Hypertensive heart disease	1	0	
Lung cancer metastatic	1	0	
Metastases to liver	0	1	
Missing	0	1	
Multiple organ dysfunction syndrome	0	2	
Myocardial infarction	0	2	
Overdose	0	1	
Pneumonia	0	2	
Sepsis	1	0	
Septic shock	1	0	
Shigella sepsis	1	0	
Unevaluable event	1	0	

Table S4 | Causes of Death from Dose 1 to Unblinding (Safety Population, \geq 16 Years Old). a. Multiple causes of death could be reported for each participant. There were no deaths among 12–15-year-old participants.

		BNT162b2 (N ^a =23,040)	(1	Placebo N ^a =23,037)		
First COVID-19 Occurrence after Dose 1		Surveillance Time ^c (n2 ^d)	n1 ^b	Surveillance Time ^c (n2 ^d)	<u>VE (%)</u>	(95% CI ^e)
Overall (≥12 years old)	131	8.412 (22,505)	1034	8.124 (22,434)	87.8	(85.3, 89.9)
Efficacy endpoint by subgroup						
Select age groups (years)						
16 to 17	3	0.094 (373)	19	0.090 (370)	84.8	(48.4, 97.1)
16 to 55	95	4.845 (12,645)	693	4.669 (12,626)	86.8	(83.6, 89.5)
>55	33	3.310 (8740)	306	3.204 (8689)	89.6	(85.0, 92.9)
≥65	12	1.645 (4455)	138	1.596 (4437)	91.6	(84.8, 95.7)
≥75	2	0.326 (905)	26	0.310 (877)	92.7	(70.7, 99.2)
Sex						
Male	70	4.355 (11,560)	500	4.115 (11,312)	86.8	(83.0, 89.9)
Female	61	4.057 (10,945)	534	4.009 (11,122)	88.7	(85.3, 91.5)
Race						
White	115	6.957 (18,538)	916	6.719 (18,479)	87.9	(85.3, 90.1)
Black or African American	6	0.783 (2042)	53	0.770 (2063)	88.9	(74.1, 96.1)
American Indian or Alaska Native	1	0.061 (216)	7	0.055 (209)	86.9	(-1.6, 99.7)
Asian	4	0.348 (995)	26	0.337 (990)	85.1	(57.0, 96.2)
Native Hawaiian or other Pacific Islander	0	0.021 (58)	1	0.011 (32)	100.0	(-2000.0, 100.0)
Multiracial	5	0.208 (565)	25	0.190 (546)	81.8	(51.6, 94.6)
Not reported	0	0.035 (91)	6	0.042 (115)	100.0	(-0.7, 100.0)
Ethnicity						
Hispanic/Latinx	52	2.351 (5701)	302	2.282 (5673)	83.3	(77.5, 87.8)
Non-Hispanic/non-Latinx	78	6.018 (16,692)	730	5.799 (16,647)	89.7	(87.0, 92.0)
Not reported	1	0.043 (112)	2	0.043 (114)	49.4	(-872.9, 99.1)
Country						
Argentina	32	1.282 (2846)	146	1.269 (2840)	78.3	(68.0, 85.7)
Brazil	14	0.554 (1430)	95	0.520 (1420)	86.1	(75.6, 92.7)
Germany	2	0.067 (246)	1	0.069 (250)	-104.5	(-11,965.9, 89.4)
South Africa	0	0.128 (367)	11	0.125 (365)	100.0	(61.1, 100.0)
Turkey	3	0.048 (246)	12	0.045 (244)	76.4	(12.4, 95.7)
USA	80	6.333 (17,370)	769	6.095 (17,315)	90.0	(87.4, 92.1)
Baseline SARS-CoV-2 status						
Positive ^f	13	0.250 (692)	17	0.265 (736)	19.2	(-76.6, 63.9)
Positive N-binding only	2	0.192 (521)	7	0.198 (542)	70.5	(-54.7, 97.0)

Positive NAAT only	10	0.020 (66)	9	0.020 (69)	-10.5	(-207.3, 59.7)
Positive NAAT and N-	1	0.038 (105)	1	0.046 (124)	-20.5	(-9359.2, 98.5)
binding						
Negative ^g	116	8.101 (21,615)	1015	7.804 (21,521)	89.0	(86.6, 91.0)
Unknown	2	0.061 (198)	2	0.055 (177)	9.7	(-1145.4, 93.5)

Table S5 | Vaccine Efficacy Overall and by Subgroup after Dose 1 During the Blinded Placebo

Controlled Follow-up Period (All-Available Population). Efficacy data are presented for participants \geq 12 years old. a. N=number of participants in the specified group. b. n1=Number of participants meeting the endpoint definition. c. Total surveillance time in 1000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for COVID-19 case accrual is from dose 1 to the end of the surveillance period. d. n2=number of participants at risk for the endpoint. e. CI for vaccine efficacy is derived based on the Clopper and Pearson method adjusted for surveillance time. f. Positive N-binding antibody result at Visit 1, positive NAAT result at Visit 1, or medical history of COVID-19. g. Negative N-binding antibody result at Visit 1, negative NAAT result at Visit 1, and no medical history of COVID-19.

		BNT162b2 (N ^a =23,040) (I		Placebo (N ^a =23,037)		
Efficacy Endpoint Subgroup	n1 ^b	Surveillance Time ^c (n2 ^d)	n1 ^b	Surveillance Time ^c (n2 ^d)	VE (%)	(95% CI ^e)
First severe COVID-19 occurrence after dose 1	1	8.439 (22,505)	30	8.288 (22,435)	96.7	(80.3, 99.9)
After dose 1 to before dose 2	0	1.351 (22,505)	6	1.360 (22,435)	100.0	(14.5, 100.0)
Dose 2 to 7 days after dose 2	0	0.425 (22,170)	1	0.423 (22,070)	100.0	(-3783.5, 100.0)
≥7 Days after dose 2	1	6.663 (22,142)	23	6.505 (22,048)	95.7	(73.9, 99.9)

 Table S6 | Vaccine Efficacy against Severe COVID-19 Occurrence after Dose 1 (All-Available

Population). Efficacy data are presented for participants ≥ 12 years old. a. N=number of participants in the specified group. b. n1=number of participants meeting the endpoint definition. c. Total surveillance time in 1000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for severe COVID-19 case accrual is from dose 1 to the end of the surveillance period for the overall row, and from the start to the end of the range stated for each time interval. d. n2=number of participants at risk for the endpoint. ^e. CI for vaccine efficacy is derived based on the Clopper and Pearson method adjusted for surveillance time. Severe COVID-19 as defined by the US FDA [https://www.fda.gov/media/137926/download]).

		BNT162b2 (N ^a =20,998)	(Placebo (N ^a =21,096)		
Efficacy Endpoint Subgroup	n1 ^b	Surveillance Time ^c (n2 ^d)	n1 ^b	Surveillance Time ^c (n2 ^d)	VE (%)	(95% CI ^e)
First COVID-19 occurrence from 7 days after dose 2						
Overall	77	6.247 (20,712)	850	6.003 (20,713)	91.3	(89.0, 93.2)
At risk ^f						
Yes	35	2.797 (9167)	401	2.681 (9136)	91.6	(88.2, 94.3)
No	42	3.450 (11,545)	449	3.322 (11,577)	91.0	(87.6, 93.6)
Age group (years) and at risk						
16–64 and at risk	29	2.083 (6632)	325	1.993 (6629)	91.5	(87.5, 94.4)
\geq 65 and at risk	6	0.680 (2322)	71	0.656 (2304)	91.8	(81.4, 97.1)
Obese ^g						
Yes	27	2.103 (6796)	314	2.050 (6875)	91.6	(87.6, 94.6)
No	50	4.143 (13,911)	536	3.952 (13,833)	91.1	(88.1, 93.5)
Age group (years) and obese						
16–64 and obese	24	1.680 (5303)	266	1.624 (5344)	91.3	(86.7, 94.5)
≥ 65 and obese	3	0.404 (1370)	45	0.410 (1426)	93.2	(78.9, 98.7)

Table S7 | Vaccine Efficacy from 7 Days after Dose 2 by Underlying Comorbidities (Risk Status) among Participants Without Evidence of Infection Prior to 7 Days after Dose 2 (Evaluable Efficacy Population). Efficacy data are presented for participants ≥ 12 years old. a. N=number of participants in the specified group. b. n1=number of participants meeting the endpoint definition. c. Total surveillance time in 1000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after dose 2 to the end of the surveillance period. d. n2=number of participants at risk for the endpoint. e. CI for vaccine efficacy is derived based on the Clopper and Pearson method adjusted for surveillance time. f. Includes participants who had ≥ 1 Charlson Comorbidity Index (CMI) category or obesity (body mass index [BMI] ≥ 30 kg/m² (≥ 16 years old] or BMI ≥ 95 th percentile [12–15 years old]). g. Participants who had BMI ≥ 30 kg/m² (≥ 16 years old) or BMI ≥ 95 th percentile (12–15 years old); refer to the CDC growth charts at https://www.cdc.gov/growthcharts/html_charts/bmiagerev.htm).

Independent Ethics Committee or Institutional Review Board Address(es)

Comité Institucional de Revisión de Ensayos Clínicos (C.I.R.E.C.) del Hospital Militar Central
"Cirujano Mayor Dr Cosme Argerich"
Av. Luis María Campos 726, Edificio PACE Piso 5
CABA, 1426
ARGENTINA
CONEP (Comissao Nacional de Etica em Pesquisa)
SRTV 701, Via W 5 Norte, lote D, Edificio PO 700, 3° andar - Asa Norte
Brasilia, DF 70719-040
BRAZIL
Comite de Etica em Pesquisa da Faculdade de Medicina do ABC\Fundacao do ABC FMABC
Avenida Lauro Gomes, 2000 - Vila Sacadura Cabral
Santo Andre/SP, 09060-870
BRAZIL
Comite de Etica em Pesquisa do Hospital Santo Antonio /Obras Sociais Irma Dulce
Avenida Luiz Tarquínio, snº, portao 9, 1º andar, sala 1, Roma
Salvador, BA 40414-120
BRAZIL
CONEP (Comissão Nacional de Ética em Pesquisa)
SRTV 701, Via W 5 Norte, lote D, Edifício PO 700, 3° andar -Asa Norte
Brasília/DF, 70719-040
BRAZIL
Landesaerztekammer Baden-Wuerttemberg
Liebknechtstr. 33
Stuttgart, 70565 GERMANY
Landesaerztekammer Baden-Wuerttemberg
Liebknechtstr. 33
Stuttgart, 70565
GERMANY
Landesaerztekammer Baden-Wuerttemberg
Liebknechtstr. 33
Stuttgart, 70565
GERMANY
Landesaerztekammer Baden-Wuerttemberg
Liebknechtstr. 33
Stuttgart, 70565
GERMANY
Landesaerztekammer Baden-Wuerttemberg
Liebknechtstr. 33
Stuttgart, 70565
GERMANY
Landesaerztekammer Baden-Wuerttemberg
Liebknechtstr. 33
Stuttgart, 70565
GERMANY
Pharma Ethics Independent Research Ethics committee
123 Amcor Road, Lyttelton Manor
Centurion, 0157
SOUTH AFRICA
Pharma-Ethics (Pty) Ltd
123 Amkor Road, Lyttelton Manor
Centurion, 0157
SOUTH AFRICA

Pharma-Ethics (Pty) Ltd
123 Amkor Road, Lyttelton Manor
Centurion, 0157
SOUTH AFRICA
Pharma-Ethics (Pty) Ltd
123 Amkor Road, Lyttelton Manor
Centurion, 0157
SOUTH AFRICA
Kocaeli Üniversitesi Klinik Arastirmalar Etik Kurulu
Kocaeli Üniversitesi Tip Fakültesi Klinik, Arastirmalar Birimi Umuttepe Yerleskesi
Kocaeli
TURKEY
Kocaeli Üniversitesi Klinik Arastirmalar Etik Kurulu
Kocaeli Üniversitesi Tip Fakültesi Klinik, Arastirmalar Birimi Umuttepe Yerleskesi
Kocaeli
TURKEY
Kocaeli Üniversitesi Klinik Arastirmalar Etik Kurulu
Kocaeli Üniversitesi Tip Fakültesi Klinik, Arastirmalar Birimi Umuttepe Yerleskesi
Kocaeli
TURKEY
Kocaeli Üniversitesi Klinik Arastirmalar Etik Kurulu
Kocaeli Üniversitesi Tip Fakültesi Klinik, Arastirmalar Birimi Umuttepe Yerleskesi
Kocaeli
TURKEY
Kocaeli Üniversitesi Klinik Arastirmalar Etik Kurulu
Kocaeli Üniversitesi Tip Fakültesi Klinik, Arastirmalar Birimi Umuttepe Yerleskesi
Kocaeli
TURKEY
Kocaeli Üniversitesi Klinik Arastirmalar Etik Kurulu
Kocaeli Üniversitesi Tip Fakültesi Klinik, Arastirmalar Birimi Umuttepe Yerleskesi
Kocaeli
TURKEY
Kocaeli Üniversitesi Klinik Arastirmalar Etik Kurulu
Kocaeli Üniversitesi Tip Fakültesi Klinik, Arastirmalar Birimi Umuttepe Yerleskesi
Kocaeli
TURKEY
Kocaeli Üniversitesi Klinik Arastirmalar Etik Kurulu
Kocaeli Üniversitesi Tip Fakültesi Klinik, Arastirmalar Birimi Umuttepe Yerleskesi
Kocaeli
TURKEY
Kocaeli Üniversitesi Klinik Arastirmalar Etik Kurulu
Kocaeli Üniversitesi Tip Fakültesi Klinik, Arastirmalar Birimi Umuttepe Yerleskesi
Kocaeli
TURKEY
NYU Langone Grossman School of Medicine IRB
One Park Ave, 6th Fl
New York, NY 10016
UNITED STATES
Western Institutional Review Board
1019 39th Ave., SE, Ste 120
Puyallup, WA 98374
UNITED STATES
Western Institutional Review Board
1019 39th Ave SE, Ste 120
Puyallup, WA 98374

UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Cincinnati Children's Hospital Medical Center IRB
•
3333 Burnet Ave, MLC 5020 Cincinnati, OH 45229
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
WCG IRB
1019 39th Ave Se, Ste 120
Puyallup, WASHINGTON 98374
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 CentreGreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board 5000 CentreGreen Way, Ste 200

Q., NG 27512
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board

5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES

Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
1 1
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 CentreGreen Way, Ste 200
Cary, NC 27513

UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
•
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 CentreGreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
WCG IRB
1019 39th Ave Se, Ste 120
Puyallup, WASHINGTON 98374
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200

Com. NC 27512
Cary, NC 27513
UNITED STATES
WESTERN INSTITUTIONAL REVIEW BOARD
1019 39th Ave S.E, Ste 120
Puyallup, WA 98374
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Kaiser Permanente Northern California Institutional Review Board
1800 Harrison St, 10th Fl
Oakland, CA 94612
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board

5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
WESTERN INSTITUTIONAL REVIEW BOARD
1019 39th Ave SE, Ste 120
Puyallup, WASHINGTON 98374-2115
UNITED STATES
WESTERN INSTITUTIONAL REVIEW BOARD
1019 39th Ave S.E, Ste 120
Puyallup, WA 98374
UNITED STATES
Western Institutional Review Board
1019 39th Ave SE, Ste 120
Puyallup, WASHINGTON 98374
UNITED STATES
Copernicus Group IRB
5000 CentreGreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
WCG IRB
1019 39th Ave Se, Ste 120
Puyallup, WASHINGTON 98374
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES

Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 CentreGreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Lehigh Valley Health Network/Institutional Review Board/Research Participant Office
1255 S Cedar Crest Blvd, Ste 3200
Allentown, PA 18103
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Western Institutional Review Board
1019 39th Ave SE, Ste 200
Puyallup, WA 98374-2115
UNITED STATES
Indian Health Service National IRB
5600 Fishers Ln, MS 09E10D
Rockville, MARYLAND 20857

UNITED STATES
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E1100
Baltimore, MARYLAND 21205
UNITED STATES
Navajo Nation Human Research Review Board
Window Rock Blvd, Administration Bldg #2, Division of Health, P.O. Box 1390
Window Rock, ARIZONA 86515
UNITED STATES
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E1100
Baltimore, MARYLAND 21205
UNITED STATES
Navajo Nation Human Research Review Board Window Boals Blud, Administration Bldg #2, Division of Health, B.O. Box 1200
Window Rock Blvd, Administration Bldg #2, Division of Health, P.O. Box 1390
Window Rock, ARIZONA 86515
UNITED STATES
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E1100
Baltimore, MARYLAND 21205
UNITED STATES
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E1100
Baltimore, MARYLAND 21205
UNITED STATES
Navajo Nation Human Research Review Board
Window Rock Blvd, Administration Bldg #2, Division of Health, P.O. Box 1390
Window Rock, ARIZONA 86515
UNITED STATES
Yale University Human Research Protection Program (Human Investigation Committee)
25 Science Park, 3rd Fl, 150 Munson St
New Haven, CT 06520
UNITED STATES
Copernicus Group IRB
5000 Centregreen Way, Ste 200
Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES Wastern Institutional Paview Poard
Western Institutional Review Board
1019 39th Ave. SE, Ste 120
Puyallup, WA 98374
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES Constraints Group Institutional Payian Poord
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 Centregreen Way, Ste 200

Cary, NORTH CAROLINA 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Western Institutional Review Board
1019 39th Ave SE, Ste 120
Puyallup, WA 98374
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Western Institutional Review Board
1019 39th Ave SE, Ste 120
Puyallup, WA 98374
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Copernicus Group Institutional Review Board
5000 CentreGreen Way, Ste 200
Cary, NC 27513
UNITED STATES
Kaiser Permanente Northern California Institutional Review Board
1800 Harrison St, 10th Fl
Oakland, CA 94612
UNITED STATES
5.1122 x11125